China Biotech Weekly #10: The GLP-1 Race Goes East — Chinese Companies Enter the $100B Obesity Market

This Week's Top Takeaway

Chinese pharmaceutical companies are entering the global GLP-1/obesity drug race — and Big Pharma is paying attention. AstraZeneca's $18.5B CSPC (石药集团) deal, Eccogene's (益方生物) $1B+ AstraZeneca partnership for an oral GLP-1, and Hansoh Pharma's (翰森制药) advancing GLP-1 pipeline all signal that China's small molecule innovation extends well beyond oncology. The global obesity drug market — projected to exceed $100B by 2030 — is the next competitive frontier for Chinese out-licensing.

BIOSECURE Watch

Status: 🟡 Steady State

OMB: continued interagency consultations, no public activity
Pentagon 1260H: no new list update since the February 13 withdrawal
SEC disclosures: approximately 13 companies
Key indicator: Federal News Network published an analysis arguing that "no federal contractor is as biotech-free as they think" — highlighting the breadth of the "biotechnology equipment or services" definition

CDE Filing Watch

Hansoh Pharma (翰森制药) filed a new IND for an oral GLP-1/GIP dual agonist — the same mechanism class as Eli Lilly's tirzepatide. This filing signals Hansoh's intent to compete in the next-generation obesity drug market with a differentiated oral formulation.

CSPC (石药集团) received CDE approval for expanded clinical development of its cardiovascular/metabolic pipeline. The approval scope is consistent with the AstraZeneca partnership's development plan.

Takeaways for BD Teams

China's out-licensing opportunity is no longer oncology-only. Cardiovascular ($18.5B AZ-CSPC), metabolic (GLP-1 landscape), and CNS (Hansoh pipeline) are emerging as the next wave. Adjust your China BD mandate to cover metabolic and cardiovascular.

Oral GLP-1 is the highest-value opportunity in the metabolic space. Eccogene's AstraZeneca deal validates Chinese oral GLP-1 innovation. There are 5+ additional Chinese oral GLP-1 programs in development. This is the scouting opportunity of 2026.

The $100B obesity market creates a new comp set for China deals. When Chinese metabolic assets start licensing at oncology-scale valuations, the total China out-licensing market could grow another 50-100% from 2025 levels.

China Biotech Weekly is published every Thursday. For questions, tips, or deal intelligence, reach out at antony@chinabiointel.com. — Antony Tan